Bortezomib and Rituximab in Newly Diagnosed Adolescent and Adult CD20-Positive Philadelphia (Ph) Negative Precursor B-Cell Acute Lymphoblastic Leukemia: A Phase II Study

Goli, Vasu Babu

Oral and Poster Abstracts
614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster I

Leukemia, ALL, Diseases, Lymphoid Malignancies

Vasu Babu Goli, MD¹^*, Hasmukh Jain, MD, DM^1,2^*, Prashant Tembhare, MD^3,4^*, Dhanlaxmi Lalit Shetty, PhD^5,6^*, Avinash Bonda, MD, DM^1,2^*, Lingaraj Nayak, MD, DM^2,7^*, Nikhil Patkar, MD^4,8^*, Papagudi Ganesan Subramanian, MD^4,9^* and Manju Sengar, MD, DM^1,10

¹Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
²Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India
³Adult & Pediatric Hematolymphoid Disease Management Group, Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
⁴Hematopathology Laboratory, Tata Memorial Centre, Mumbai, India
⁵Adult Hematolymphoid Disease Management Group, Department of Medical Oncology, ACTREC, Navi Mumbai, Maharashtra, IND
⁶Adult Hematolymphoid Disease Management Group, Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
⁷Bone Marrow Transplant Unit, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre., Navi Mumbai., India
⁸Haematopathology Laboratory, Tata Memorial Hospital, Navi Mumbai, India
⁹Hematopathology Laboratory, ACTREC, Tata Memorial Centre, Mumbai, Maharashtra, India
¹⁰Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, Maharashtra, India

BACKGROUND

The expression of CD20 in precursor B-cell ALL has been associated with poor outcomes. The addition of rituximab with intensive chemotherapy in this subset of ALL has led to improvement in the event-free survival. Further increment in outcomes require novel approaches. Bortezomib is an active drug in relapsed ALL as well as has synergistic activity with rituximab in B-cell lymphomas; thus the addition of bortezomib to rituximab and chemotherapy may improve the outcomes in CD20-positive precursor B-cell ALL.

METHODS

We conducted a phase II study to test the activity of bortezomib and rituximab in combination with a paediatric inspired regimen during induction therapy in newly diagnosed adolescent and adults (>14 years of age) with CD20-positive, Philadelphia (Ph)-negative precursor B-ALL, with bone marrow measurable residual disease (MRD) negativity at the end of induction (EOI) as the primary endpoint.

Results:

From December 2017 through August 2019, a total of 35 patients were enrolled. A total of 70.99% patients achieved EOI MRD negative status. MRD negative rates improved to 88% post consolidation. There was no significant increase in toxicity with addition of bortezomib and rituximab to standard chemotherapy. The incidence of neuropathy was 26% (<grade 3). After a median follow up of 18 months, event-free survival and overall survival were 81.8% and 84.7%, respectively.

Conclusion:

The combination of bortezomib, rituximab and paediatric-inspired ALL regimen is active and well tolerated in in de-novo CD20 positive Ph-negative precursor B-ALL.

Disclosures: No relevant conflicts of interest to declare.

See more of: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster I
See more of: Oral and Poster Abstracts

<< Previous Abstract | Next Abstract

^*signifies non-member of ASH

1024 Bortezomib and Rituximab in Newly Diagnosed Adolescent and Adult CD20-Positive Philadelphia (Ph) Negative Precursor B-Cell Acute Lymphoblastic Leukemia: A Phase II Study